Polymeric marker with high radiopacity for use in medical devices
16 claims: 16 independent, 0 dependent
- 1A radiopaque marker, comprising:a) a polymer matrix,b) radiopaque particles disposed within said polymer matrix having an average diameter of at least 2 microns and a maximum diameter of about 20 microns;andc) a wetting agent different from the polymer matrix for facilitating encapsulation of said particles by said polymer such that the radiopaque particles comprise 90.8 to 93.2 weight percent of the marker, wherein said polymer is polyether block amide and said radiopaque particles are tungsten powder. Marqueur radio-opaque, comprenant : a) une matrice polymère,b) des particules radio-opaques disposées à l'intérieur de ladite matrice polymère ayant un diamètre moyen d'au moins 2 microns et un diamètre maximal d'environ 20 microns ;etc) un agent mouillant différent de la matrice polymère permettant de faciliter l'encapsulation desdites particules par ledit polymère de sorte que les particules radio-opaques comprennent de 90,8 à 93,2 pour cent en poids du marqueur, où ledit polymère est un polyéther bloc amides et lesdites particules radio-opaques sont une poudre de tungstène. Strahlenundurchlässiger Marker, der Folgendes aufweist: a) eine Polymermatrix,b) strahlenundurchlässige Partikel, die innerhalb der Polymermatrix angeordnet sind und einen durchschnittlichen Durchmesser von wenigstens 2 Mikrometern und einen maximalen Durchmesser von ungefähr 20 Mikrometern aufweisen;undc) ein Benetzungsmittel, das sich von der Polymermatrix unterscheidet, zur Erleichterung einer Einkapselung der Partikel durch das Polymer, so dass die strahlenundurchlässigen Partikel 90,8 bis 93,2 Gew.-% des Markers aufweisen, wobei das Polymer Polyetherblockamid ist und die strahlenundurchlässigen Partikel Wolframpulver sind.
- 2Marqueur radio-opaque de la revendication 1, dans lequel les particules radio-opaques comprennent 91,3 pour cent en poids du marqueur. Strahlenundurchlässiger Marker nach Anspruch 1, wobei die strahlenundurchlässigen Partikel 91,3 Gew.-% des Markers aufweisen. The radiopaque marker of claim 1, wherein the radiopaque particles comprise 91.3 weight percent of the marker.
- 3Marqueur radio-opaque de la revendication 1, dans lequel ledit agent mouillant comprend une polyoléfine greffée d'anhydride maléique. Strahlenundurchlässiger Marker nach Anspruch 1, wobei das Benetzungsmittel Maleinsäureanhydrid-Pfropfpolyolefin aufweist. The radiopaque marker of claim 1, wherein said wetting agent comprises maleic anhydride graft polyolefin.
- 4Marqueur radio-opaque de la revendication 1, dans lequel lesdites particules radio-opaques sont sensiblement équiaxes. Strahlenundurchlässiger Marker nach Anspruch 1, wobei die strahlenundurchlässigen Partikel im Wesentlichen gleichachsig sind. The radiopaque marker of claim 1, wherein said radiopaque particles are substantially equiaxed.
- 5Marqueur radio-opaque de la revendication 4, dans lequel lesdites particules sont sensiblement sphériques. Strahlenundurchlässiger Marker nach Anspruch 4, wobei die Partikel im Wesentlichen kugelförmig sind. The radiopaque marker of claim 4, wherein said particles are substantially spherical.
- 6Marqueur radio-opaque de la revendication 1, comprenant en outre un antioxydant. Strahlenundurchlässiger Marker nach Anspruch 1, der ferner ein Antioxidationsmittel aufweist. The radiopaque marker of claim 1, further comprising an antioxidant.
- 7Marqueur radio-opaque de la revendication 1, dans lequel ledit polymère est thermoplastique. Strahlenundurchlässiger Marker nach Anspruch 1, wobei das Polymer thermoplastisch ist. The radiopaque marker of claim 1, wherein said polymer is thermoplastic.
- 8Marqueur radio-opaque de la revendication 1, formé de manière à définir une structure tubulaire. Strahlenundurchlässiger Marker nach Anspruch 1, der so gebildet ist, dass er eine röhrenförmige Struktur definiert. The radiopaque marker of claim 1, formed so as to define a tubular structure.
- 9A method of radiopaquely marking a medical device (16, 22, 30) comprising:a) providing a flexible polymeric radiopaque marker containing greater than 30 volume percent and 90.8 to 93.2 weight percent radiopaque particles in a polymer matrix with a wetting agent different from the polymer matrix, wherein such particles comprise tungsten powder and have an average diameter of at least 2 microns and a maximum diameter of about 20 microns and said polymer comprises polyether block amide;b) accurately positioning said marker on said medical device (16, 22, 30) , andc) melt bonding said marker in place. Procédé de marquage de manière radio-opaque d'un dispositif médical (16, 22, 30) comprenant le fait : a) de fournir un marqueur radio-opaque polymère souple contenant plus de 30 pour cent en volume et de 90,8 à 93,2 pour cent en poids de particules radio-opaques dans une matrice polymère avec un agent mouillant différent de la matrice polymère, où telles particules comprennent une poudre de tungstène et ont un diamètre moyen d'au moins 2 microns et un diamètre maximal d'environ 20 microns et ledit polymère comprend un polyéther bloc amides ;b) de positionner avec précision ledit marqueur sur ledit dispositif médical (16, 22, 30), etc) de lier par fusion ledit marqueur en place. Verfahren zur strahlenundurchlässigen Markierung einer medizinischen Vorrichtung (16, 22, 30), das Folgendes aufweist: a) Bereitstellen eines flexiblen polymerischen strahlenundurchlässigen Markers, der mehr als 30 Vol.-% und 90,8 bis 93,2 Gew.-% an strahlenundurchlässigen Partikeln in einer Polymermatrix enthält, wobei sich ein Benetzungsmittel von der Polymermatrix unterscheidet, wobei derartige Partikel Wolframpulver aufweisen und einen durchschnittlichen Durchmesser von wenigstens 2 Mikrometern und einen maximalen Durchmesser von ungefähr 20 Mikrometern aufweisen und das Polymer Polyetherblockamid aufweist;b) akkurates Positionieren des Markers auf der medizinischen Vorrichtung (16, 22, 30), undc) Schmelzverbinden des Markers an der Stelle.
- 10Procédé de la revendication 9, comprenant en outre le fait de disposer une longueur de tube thermorétrécissable autour dudit marqueur positionné avec précision et de chauffer ledit tube. The method of claim 9, further comprising disposing a length of heat shrink tubing about said accurately positioned marker and heating said tubing. Verfahren nach Anspruch 9, das ferner ein Anordnen einer Länge eines Schrumpfschlauchs um den akkurat positionierten Marker und ein Erwärmen des Schlauchs aufweist.
- 11Procédé de la revendication 9, dans lequel ledit dispositif médical comprend un cathéter à ballonnet (16) et ledit marqueur est positionné sur un élément interne disposé à l'intérieur d'un ballonnet dilatable (18). The method of claim 9, wherein said medical device comprises a balloon catheter (16) and said marker is positioned on an inner member disposed within an expandable balloon (18). Verfahren nach Anspruch 9, wobei die medizinische Vorrichtung einen Ballonkatheter (16) aufweist und der Marker an einem inneren Element positioniert ist, das innerhalb eines expandierbaren Ballons (18) angeordnet ist.
- 12Procédé de la revendication 9, dans lequel ledit dispositif médical comprend un fil-guide (22, 30). The method of claim 9, wherein said medical device comprises a guidewire (22, 30). Verfahren nach Anspruch 9, wobei die medizinische Vorrichtung einen Führungsdraht (22, 30) aufweist.
- 13Procédé de la revendication 12, dans lequel une pluralité desdits marqueurs sont liés audit fil-guide (22, 30). The method of claim 12, wherein a plurality of said markers are bonded to said guidewire (22, 30). Verfahren nach Anspruch 12, wobei eine Mehrzahl der Marker mit dem Führungsdraht (22, 30) verbunden ist.
- 14Procédé de la revendication 13, dans lequel lesdits marqueurs sont équidistants les uns par rapport aux autres de manière à fonctionner comme une règle sous contrôle fluoroscopique. The method of claim 13, wherein said markers are equally spaced relative to one another so as to function as a ruler under fluoroscopic inspection. Verfahren nach Anspruch 13, wobei die Marker relativ zueinander gleichmäßig beabstandet sind, so dass sie bei einer Durchleuchtungsprüfung als Lineal dienen.
- 15Procédé de la revendication 13, dans lequel ledit fil-guide (22, 30) comporte une caractéristique radio-opaque et dans lequel lesdits marqueurs sont placés chacun à une distance présélectionnée de ladite caractéristique. The method of claim 13, wherein said guidewire (22, 30) includes a radiopaque feature and wherein said markers are each spaced a preselected distance from said feature. Verfahren nach Anspruch 13, wobei der Führungsdraht (22, 30) ein strahlenundurchlässiges Merkmal einschließt und wobei die Marker jeweils mit einem vorausgewählten Abstand von dem Merkmal beabstandet sind.
- 16Procédé de la revendication 13, dans lequel lesdits marqueurs présentent chacun une longueur différente de manière à fonctionner en tant que jauges sous contrôle fluoroscopique. The method of claim 13, wherein said markers each have a different length so as to function as gauges under fluoroscopic inspection. Verfahren nach Anspruch 13, wobei die Marker jeweils eine unterschiedliche Länge aufweisen, so dass sie bei einer Durchleuchtungsprüfung als Messgerät dienen.
Independent claims16
42 paragraphs in 2 sections, as filed
BACKGROUND OF THE INVENTION
The present invention is directed to elongated intracorporeal devices, and more particularly intraluminal devices for stent deployment, percutaneous transluminal coronary angioplasty (PICA), and - similar procedures. PTCA is a widely used procedure for the treatment of coronary heart disease. In this procedure, a balloon dilatation catheter is advanced into the patient's coronary artery and the balloon on the catheter is inflated within the stenotic region of the patient's artery to open up the arterial passageway and increase the blood flow through the artery. To facilitate the advancement of the dilatation catheter into the patient's coronary artery, a guiding catheter having a preshaped distal tip is first percutaneously introduced into the cardiovascular system of a patient by the Seldinger technique through the brachial or femoral arteries. The catheter is advanced therein until the preshaped distal tip of the guiding catheter is disposed within the aorta adjacent the ostium of the desired coronary artery. A balloon dilatation catheter may then be advanced through the guiding catheter into the patient's coronary artery until the balloon on the catheter is disposed wthin the stenotic region of the patient's artery.
Once properly positioned across the stenosis, the balloon is inflated one or more times to a predetermined size with radiopaque liquid at relatively high pressures (e.g., generally 4-12 atmospheres (405.3kPa-1215.9kPa)) to dilate the stenosed region of a diseased artery. After the inflations, the balloon is finally deflated so that the dilatation catheter can be removed from the dilatated stenosis to resume blood flow.
Similarly, balloon catheters may be used to deploy endoprosthetic devices such as stents. Stents are generally cylindrical shaped intravascular devices that are placed within a damaged artery to hold it open. The device can be used to prevent restenosis and to maintain the patency of blood vessel immediately after intravascular treatments. Typically, a compressed or otherwise reduced diameter stent is disposed about an expandable member such as a balloon on the distal end of the catheter, and the catheter and stent thereon are advanced through the patient's vascular system. Inflation of the balloon expands the stent within the blood vessel. Subsequent deflation of the balloon allows the catheter to be withdrawn, leaving the expanded stent within the blood vessel.
Typically, the distal section of a balloon catheter or other percutaneous device will have one or more radiopaque markers in order for the operator of the device to ascertain its position and orientation under X-ray or fluoroscopy imaging. Generally, a band or ring of solid radiopaque metal is secured about an inner or outer shaft of a balloon catheter to serve as a radiopaque marker. Such a configuration, however, locally stiffens the catheter shaft and thereby imparts an undesirable discontinuity thereto as the solid metal band is relatively inflexible compared to a polymer balloon catheter shaft. Additionally, metallic markers are relatively expensive to manufacture and relatively difficult to positively affix to an underlying device.
As is described in <patcit id="pcit0001" dnum="US6540721B"><text>U.S. Patent No. 6,540,721</text></patcit>, many of the problems associated with the use of conventional markers may be overcome by replacing the rigid precious metal tubing with a polymer that is filled or doped with a suitable radiopaque agent. Such a marker may be formed by blending a polymer resin with a powdered, radiographically dense material such as elemental tungsten and then extruding the composition to form a tubular structure with an appropriate inner diameter and wall thickness. The extrusion may then be cut to discrete lengths and installed onto the intended component via a melt bonding process.
A shortcoming of such an approach has been found to be the apparent limit to which a suitable polymer can be filled with a radiographically dense material to yield a composition that can be successfully compounded, economically shaped into suitable dimensions for markers and easily assembled onto a component without unduly compromising the desirable properties of the polymer matrix. The fill ratio that is achievable will determine how thick a marker must be in order to achieve a particular degree of radiopacity. In the case of tungsten in a polymer such as Pebax (polyether block amide), the fill ratio limit has heretofore been found to be about 80 weight percent. Such a weight percentage equates to about 18 volume percent which requires the marker to be excessively thick in order to achieve adequate radiopacity.
In <patcit id="pcit0002" dnum="WO02096474A"><text>WO 02/096474</text></patcit> there is described an acrylic radiopaque bone cement for orthopaedic use comprising a solid phase composed of a mixture of at least one poly(methyl acrylate)-based polymer, one free-radial polymerization initiator and one or more substances opaque to X rays, and a liquid phase substantially composed of a mixture of at least one monomer, one accelerator and one stabilizer. The radiopaque substances comprise metallic tungsten and tantalum particles, compounds or mixtures thereof, covered with a polymer coating compatible with said bone cement. The coating layer of the particles of radiopaque substances is an acrylic polymer based on poly(methyl methacrylate). The amount of radiopacifying element is between 1 and 20% by weight, relative to the solid phase, preferably between 2% and 5% by weight, relative to the solid phase. By contrast, in <patcit id="pcit0003" dnum="US4935019A"><text>US 4,935,019</text></patcit> there is described a radiopaque, polymeric composition suitable for printing onto surgical fabrics to provide an X-ray detectable marker. This is obtained by dispersing a heavy metal salt such as barium sulfate in a liquid polymer carrier. The barium sulfate has an average particle size greater than about 5 microns and is present in an amount of from about 15 to 90% by weight of total solids of the composition. In <patcit id="pcit0004" dnum="US2001021873A"><text>US 2001/021873</text></patcit> there is described a temporary bioabsorbable-radiopaque marker for use on an implantable endoprosthesis. The bioabsorbable-radiopaque marker is adapted to be disposed on or adjacent an implantable endoprosthesis in a body lumen for a predetermined amount of time until the bioabsorbable and radiopaque materials are absorbed or dispersed in the body. While in <patcit id="pcit0005" dnum="WO03089012A"><text>WO 03/089012</text></patcit> there are described materials, devices and methods for marking biopsy sites for a limited time. The biopsy-marking materials are ultrasound-detectable bio-resorbable powders, with powder particles typically between about 20 microns and about 800 microns in maximum dimension, more preferably between about 300 microns and about 500 microns. The powders may be formed of polymeric materials containing cavities sized between about 10 microns and about 500 microns, and may also contain binding agents, anesthetic agents, hemostatic agents, and radiopaque markers.
In <patcit id="pcit0006" dnum="US4714721A"><text>US 4,714,721</text></patcit> there are described composite materials for prosthesis purposes which consist of a plastics matrix and an inorganic radiopaque filler which, as the essential components, contains a combination of compounds of the elements Gd, Sr and, if appropriate, La. The proportion of filler in the total composite material is between 20 and 90% by weight.
In <patcit id="pcit0007" dnum="US20030164063A"><text>US 2003/0164063</text></patcit> tungsten/polymer composites are described comprising tungsten powder, another metal powder having a high packing density, and an organic binder. Such composites are said to be useful as lead replacements, particularly in the manufacture of shot.
In <patcit id="pcit0008" dnum="EP0987042A2"><text>EP-A2-0, 987, 042</text></patcit> there is described a radiopaque marker for the body portion of a medical catheter, and the methods for manufacturing such a marker which require the blending of a metal with a polymer matrix. For the blend, the metal is preferably greater than approximately seventy percent by weight. This blend is then made into a band having a thickness that is less than about 0.05mm (two thousandths of an inch). To assemble the catheter, the radiopaque band is positioned against the catheter body and the band is then thermally bonded to the catheter body. For a balloon catheter, the catheter body is tubular and the radiopaque marker band can be formed as a ring that will surround the catheter body, circumscribe the lumen inside the catheter body, or be incorporated as part of the catheter body. The position of the marker band can be established as desired and then thermally bonded onto the catheter body to identify the location of the balloon on the catheter body.
A polymeric marker is therefore needed having a substantially higher fill ratio than has heretofore been possible. Such a marker would allow devices to be rendered highly visible without an inordinate increase in overall profile nor a compromise of the flexibility of the underlying component.
<u>SUMMARY OF THE INVENTION</u>
The invention is directed to a polymeric radiopaque marker for a medical device. In particular, the present invention provides a radiopaque marker having the features of claim 1.
The present invention overcomes the shortcomings of previously described polymeric radiopaque markers by enabling a polymer to be filled or doped with a considerably greater quantity of a radiopaque agent than has heretofore been achievable. The increased fill ratio nonetheless allows uniform pellets to be compounded and an extrusion with the appropriate wall thickness to be formed. The resulting marker provides an unprecedented combination of radiopacity and flexibility. Such a marker would allow any of various intraluminal devices to be radiopaquely marked including, but not limited to, coronary, and peripheral balloon catheters, stent delivery catheters, and guiding catheters as well as guidewires.
Embodiments of the present invention rely on the use of radiopaque materials with a preselected particle shape and a preselected particle size distribution as well as the inclusion of one or more additives in the polymer/radiopaque agent blend. A multifunctional polymeric additive is added to the composition in order to enhance the wetting, adhesive and flow properties of the individual radiopaque particles by the polymer so as to cause each particle to be encapsulated by the polymer and thereby allow the polymer to form a continuous binder. An antioxidant may optionally be added in order to preserve the high molecular weight of the polymer matrix as it is exposed to the high temperatures and shear stresses associated with the compounding and extrusion processes.
While previous attempts to increase fill ratios have involved tungsten powder of relatively fine particle size, the present invention relies on the use of particles of increased size in order to achieve such an end. An increase in particle size has been found to allow the polymer to more effectively function as a continuous binder and thereby increase ductility at a given fill ratio or maintain ductility at increased fill ratios. It has been found that in constraining the average particle size to at least 2 microns and limiting maximum particle size to about 20 microns provides the desired results. In the case of tungsten in polyether block amide (Pebax), a fill ratio of about 91.3 weight percent (equivalent to 36.4 volume percent) or more is readily attainable. The fill ratio is about 90.8 weight percent (34.9 volume percent) to about 93.2 weight percent (42.7 volume percent). Additionally, it has been found that the process by which the tungsten powder is produced has a considerable effect on both particle size distribution as well as the shape of the individual particles. Tungsten powder produced by either a "pusher" process or "atomization" process, then milled and classified has been found to provide discrete particles having a more equiaxed shape and size respectively and are therefore more ideally suited for the purposes of the present invention than powders produced employing a "rotary" process.
The marker of the present invention is manufactured by first tumble mixing the polymer resin with a pelletized wetting agent, such as maleic anhydride graft polyolefin resin (MA-g-PO), and an antioxidant and then introducing the mixture into the primary feeder of a twin screw extruder. The mixture is fed in at a controlled mass flow rate and conveyed down the barrel length as it is heated above its melting temperature and blended. At a point downstream, tungsten powder is introduced into the mix at a controlled mass flow rate via a secondary feeder. The tungsten powder and the molten ingredients become intimately intermixed as they are conveyed downstream and discharged through a die as molten strands which are cooled in water and subsequently pelletized. The markers are subsequently formed by extruding the tungsten filled polymer onto a continuous beading of PTFE and drawn down to yield the desired wall thickness. The extrusion tolerances are such that the outer diameter of the extrusion can vary by as much as 0-0254mm (0.001 inch) which is large enough to significantly affect the radiopacity and profile of the finished marker. Consequently, in a presently preferred embodiment, the extrusion is hot die necked (i.e., the extruded tube on a support mandrel, such as the PTFE beading, is pulled through a heated die to take on the die size), to resize the outer diameter and provide the desired wall thickness. The extrusion is then cut to the desired lengths, preferably with the beading still in place so as to provide support. Removal of the beading remnant then allows the marker to be slipped onto the medical device or component thereof to be marked and melt bonded in place. The polymeric, marker is typically a closed, solid-walled band with a tubular or annular shape. However, the polymeric marker can have a variety of suitable shapes. Reliance on melt bonding obviates the feed for the marker to completely surround the underlying device. Markers can for example be longitudinally split in half to form two markers of C-shaped cross-section. Or, solid strands of extruded marker material may be melt bonded to one side to form one or more longitudinal stripes or helical patterns.
During melt bonding, the polymeric marker is heated to an elevated temperature sufficient to melt the polymeric material to produce the melt bond. However, in one presently preferred embodiment, the elevated temperature is low enough to minimize or prevent flowing of the polymeric material of the marker. Consequently, the double wall thickness (inner diameter minus outer diameter) of the polymeric marker after melt bonding is equal to or not substantially less than (i.e., not more than about 5 to about 25% less than) the double wall thickness prior to melt bonding. Although some rounding of the edges of the polymeric marker may occur during melt bonding, the maximum wall thickness of the polymeric marker is preferably not reduced during the melt bonding. The marker radiopacity is strongly affected by both the percent loading of radiopaque material and the final wall thickness of the marker. Consequently, the percent loading of radiopaque material and the wall thickness of the finished marker are carefully controlled to provide the desired radiopacity. If the wall thickness of the polymeric marker is less than the required minimum wall thickness, the radiopacity of the marker will be too low. On the other hand, if the outer diameter/wall thickness of the polymeric marker is greater than the required maximum outer diameter/wall thickness, the large profile and added stiffness of the marker will disadvantageously affect catheter performance. Thus, the hot die necked extrusion has an outer diameter and wall thickness which is within the minimum and maximum desired values, so that little or no thinning of the marker is required during melt bonding of the marker to provide the desired outer diameter. As a result, a decrease in wall thickness which can reduce the radiopacity of the finished marker is prevented or minimized during bonding. In one embodiment, the polymeric marker is adhesively bonded to the medical device or component, and as a result, the wall thickness of the marker is not affected by the bonding process.
Due to its high radiopacity, flexibility and melt bondability, the marker of the present invention is readily attached to for example the inner member of a balloon catheter, a guidewire, and even a guide catheter tip. The attachment of radiopaque markers of known dimensions to a guidewire or the attachment to a guidewire of multiple radiopaque markers with known separation distances impart a measurement capability to the catheter that allows a physician to quickly and easily measure lesions and decide on appropriate stent lengths.
These and other features of the present invention will become apparent from the following detailed description of preferred embodiments which, taken in conjunction with the accompanying drawings, illustrate by way of example the principles of the present invention.
BRIEF DESCRIPTION OF THE DRAWINGS
<ul id="ul0001" list-style="none" compact="compact"><li><figref idref="f0001">Figure 1</figref> is an enlarged side view of the radiopaque markers of the present invention attached to a balloon catheter;</li><li><figref idref="f0001">Figure 2</figref> is an enlarged side view of radiopaque markers of the present invention attached to a guidewire in a preferred configuration; and</li><li><figref idref="f0001">Figure 3</figref> is an enlarged side view of the radiopaque markers of the present invention attached to a guidewire in an alternatively preferred configuration.</li></ul>
<u>DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS</u>
The present invention provides a radiopaque marker for use on a variety of devices that is flexible, highly radiopaque and is easily attachable to such devices by melt bonding. These properties allow markers to be of minimal thickness and thereby minimize the effect the marker has on the overall profile and stiffness of the device to which it is to be attached.
In order to achieve the high fill ratios that are necessary to attain the desired radiopacity and in order to do so without compromising the compoundability and workability of the polymeric material nor its ultimate strength and flexibility, a number of different parameters have been found to be of importance. More specifically, both the particle shape and particle size of the radiopaque agent must be carefully controlled while the inclusion of a wetting agent such as maleic anhydride graft polyolefin resin (MAg-PO) in the polymer blend is critical. An antioxidant may additionally be included in an effort to reduce the adverse effect the high processing temperatures and shear stresses may have on polymer properties.
A number of polymeric materials are well suited for use in the manufacture of markers. The material preferably comprises a low durometer polymer in order to render the marker sufficiently flexible so as not to impair the flexibility of the underlying medical device component to which the finished marker is to be attached. Additionally, the polymer is preferably compatible with the polymeric material of which the component is constructed so as to allow the marker to be melt bonded in place. For example, in one arrangement the polymeric marker and at least an outer layer of the catheter shaft are formed of the same class of polymer (e.g., polyamides) so that they are melt bondable together. In another example, the polymeric markers are installed on a dissimilar class of polymeric substrate, and are retained in position by adhesion or dimensional interference. The polymer must also impart sufficient strength and ductility to the marker compound so as to facilitate its extrusion and forming into a marker, its subsequent handling and attachment to a medical device and preservation of the marker's integrity as the medical device is flexed and manipulated during use. Examples of such polymers include but are not limited to polyamide copolymers like polyether block amide (Pebax), polyetherurethanes like Pellethane, polyester copolymers like Hytrel, olefin derived copolymers, natural and synthetic rubbers like silicone and Santoprene, thermoplastic elastomers like Kraton and specialty polymers like EVA and ionomers, etc. as well as alloys thereof. A Shore durometer of not greater than about 63D to about 25D is preferred. The polymer used in the manufacture of a marker in accordance with the present invention is polyether block polyamide copolymer (PEBAX), preferably with a Shore durometer of about 40D. However, other classes of polymers allowing for lower durometers may be used in radiopaque markers, such as polyurethanes, which may provide greater flexibility.
A number of different metals are well known to be radiographically dense and can be used in a pure or alloyed form to mark medical devices so as to render them visible under fluoroscopic inspection. Commonly used metals include but are not limited to platinum, gold, iridium, palladium, rhenium and rhodium. Less expensive radiopaque agents include tungsten, tantalum, silver and tin, of which tungsten is used in the markers of the present invention.
The control of particle size has been found to be of critical importance for achieving the desired ultra high fill ratios. While efforts to increase fill ratios have previously utilized small average particle sizes (1 micron or less) so as to minimize the ratio of particle size to as-extruded wall thickness, it has been found that higher fill percentages can be realized with the use of somewhat larger average particles sizes. It is desirable in the formulation of high fill ratio compounds to have the following attribute: 1) uniform distribution of the filler particles, and 2) continuity of the surrounding polymer matrix, and 3) sufficient spacing between filler particles so that the polymer matrix provides ductility to the bulk mixture to impart processability in both the solid and molten state.
The use of larger average particle sizes results in greater spacing between filler particles at a given percentage, thus maintaining processability during compounding and especially subsequent extrusion coating. The upper limit of average particle size is determined by the wall thickness of the coating and the degree of non-uniformity tolerable (i.e., surface defects). It has been found that a particle size distribution having an average particle size range of at least 2 microns to 10 microns and a maximum particle size of about 20 microns yields the desired fill ratio and provides for a smooth surface in the marker made therefrom.
The control of particle shape has also been found to be of critical importance for achieving the desired ultra high fill ratios. Discrete particles of equiaxed shape have been found to be especially effective, as individual particles of irregular shape, including agglomerations of multiple particles, have been found to adversely impact the surface, and thus, the maximum fill ratio that is attainable.
It has also been found that the process by which certain metal powders are produced has a profound effect on the shape of the individual particles. In the case of metallic tungsten, the powders may be formed by the reduction of powdered oxides through either "rotary", "pusher" or "atomization" processing. Of these processes, "rotary" processing has been found to yield the least desirable shape and size distribution as partial sintering causes coarse agglomerates to be formed which do not break up during compounding or extrusion and thus adversely effect the marker manufactured therefrom. Atomized powders have been reprocessed by melting and resolidifying "rotary" or "pusher" processed powders and result in generally equiaxed, discrete particles which are suitable for use in the present invention. "Pusher" processed powders are preferred due to their low cost and discrete, uniformly shaped particles.
In order for the polymer to most effectively encapsulate individual radiopaque particles, it is necessary for a low-energy interface to exist between such particles and the polymer so as to enable the polymer to "wet" the surface of the particles. The materials should have similar surface energies to be compatible. For materials which do not naturally have similar surface energies, compatibility can be promoted by generating a similar surface energy interface, i.e., a surface energy interface which is intermediate between the natural surface energies of the materials. Certain additives such as surfactants and coupling agents may serve as wetting agents and adhesion promoters for polymer/metal combinations that are not naturally compatible. It has been found that additives containing maleic anhydride grafted to a polyolefin backbone provide a significant benefit in this regard wherein materials commercially available as Lotader 8200 (having LLDPE Backbone) and Licomont AR504 (having PP backbone) were found to be particularly effective for use with tungsten polyether block amide (Pebax) combinations. Emerging extrusions were found to be less susceptible to breakage and the melt viscosity during compounding was lower as was manifested by a reduction in torque exerted during the extrusion process. The use of such additives allowed compounds with higher fill ratios to be successfully produced.
The inclusion of an antioxidant in the marker composition has also been found to be of benefit. Commercially available antioxidants such as Irganox B225 or Irganox 1010, have been found to minimize degradation (i.e., reduction in molecular weight) of the polymer matrix as it is exposed to the multiple heat and shear histories associated with the compounding, extrusion, and bonding processes.
The compound used for the manufacture of the marker of the present invention is preferably made by first blending the polymer resin and wetting agent, and optionally, an antioxidant such as by tumble mixing after which such blend is introduced into a twin-screw extruder via a primary feeder. The feed rate is carefully controlled in terms of mass flow rate to ensure that a precise fill ratio is achieved upon subsequent combination with the radiopaque agent. The heat that the materials are subjected to as they are conveyed through the extruder causes the polymer to melt to thereby facilitate a thorough homogenization of all of the ingredients. The radiopaque agent powder, selected for its uniform particle shape and controlled particle size distribution as described above is subsequently introduced into the melt stream via a secondary feeder, again at a carefully controlled mass flow rate so as to achieve the target fill ratio. The solid powder, molten polymer and additives are homogenized as they are conveyed downstream and discharged through a die as molten strands which are cooled in water and subsequently pelletized. The preferred extrusion equipment employs two independent feeders as the introduction of all the components through a single primary feeder would require significantly higher machine torques and result in excessive screw and barrel wear. The powder feeder is preferentially operated in tandem with a sidefeeder device, which in turn conveys the powder through a sealed main barrel port directly into the melt stream. A preferred composition comprises a fill ratio of 90.8 weight percent of tungsten (H.C. Starck's Kulite HC600s, HC180s and KMP-103JP) to polyether block amide (Pebax) 40D. A maleic anhydride source in the form of Licomont AR504 is initially added to the polymer resin at the rate of approximately 3 pphr while an antioxidant in the form of Ciba Geigy Irganox B225 at the rate of approximately 2 pphr (parts per hundred relative to the resin). The temperature to which the materials are subjected to in the extruder is about 221°C.
Once the marker material has been compounded, the marker can be fabricated in suitable dimensions by an extrusion coating process. While free extrusion is possible, this method is problematic due to the high fill ratios of the polymeric materials. Extrusion onto a continuous length of beading has been found to lend the necessary support for the molten extrudate to prevent breakage. The support beading may take the form of a disposable, round mandrel made of PTFE, (Teflon) coated stainless steel wire or other heat resistant material that does not readily bond to the extrudate. By additionally limiting the area draw down ratio (ADDR) to below 10:1 the tungsten-laden melt can successfully be drawn to size by an extrusion puller. The beading provides the added benefit of fixing the inner diameter and improving the overall dimensional stability of the final tungsten/polymer coating. Extrusions of the 91.3 weight percent fill ratio tungsten polyether block amide (Pebax) composition described above over 0.5461mm (0.0215") diameter PTFE beading were successfully drawn down to a wall thickness of 0.0635mm (0.0025") to yield a marker properly sized for attachment to for example a 0.5588mm (0.022") diameter inner member of a balloon catheter. Also, extrusion coatings of 91% compound over 0.1778mm (0.007") Teflon coated stainless steel wire were successfully drawn down to single wall thicknesses of 0.0508mm (0.002") to make guidewire coatings.
In one embodiment, once the extrudate has cooled, the extrusion is simply cut to the desired lengths (e.g., 1 to 1.5 mm) of the individual markers, such as with the use of a razor blade and reticle, preferably with the beading still in place to provide support during cutting. The beading remnant is subsequently ejected and the marker is slipped onto a medical device or a particular component thereof. In one embodiment, a segment of the extrude is hot die necked with the beading inside to resize the outer diameter and wall thickness of the extrudate prior to cutting into individual markers. For example, an extrudate, having an inner diameter of about 0.05461 ± 0.0127mm (0.0215 ± 0.0005 inches) and an outer diameter of about 0.6985 ± 0.0254mm (0.0275 ± 0.001 inches), is hot die necked to an outer diameter of about 0.6731mm (0.0265 inches) to produce a double wall thickness of about 0.127 ± 0.127mm (0.005 ± 0.005 inches). To minimize part to part variability in double wall thickness, the actual hot die size may be selected based upon the actual beading diameter prior to hot die necking.
Finally, the marker is attached to the underlying substrate, preferably with the use of heat shrink tubing and a heat source (hot air, laser, etc.) wherein the heat (∼171-210°C) simultaneously causes the marker to melt and the heat shrink tubing to exert a compressive force on the underlying molten material. To prevent extensive dimensional changes (e.g., thinning) of the polymeric marker, the temperatures used are below the melting temperature, thereby relying on heat and pressure to soften the marker and generate an adhesive bond with the underlying substrate. For markers formed of polyether block amide (PEBAx) 40D, the temperature used is about 124-135°C.
Heat bonding a marker onto an underlying component provides the added benefit of slightly tapering the edges of the marker to reduce the likelihood of catching an edge and either damaging the marker or the medical device during assembly or handling of the medical device.
A marker formed as per the above described compounding, fabricating and assembling processes, having a fill ratio of 91.3 weight percent (36.4 volume percent) with a wall thickness of 0.0635mm (0.0025") has been shown to have dramatically more radiopacity than commercially available 80 weight percent compounds and comparable to the radiopacity of 0.03175mm (0.00125") thick conventional Platinum/10% Iridium markers. The radiopacity is a function of the total volume of radiopaque material present in the marker (i.e., the product of the volume % and the volume of the marker). In a presently preferred embodiment, the marker is about 1.5 mm long and has a double wall thickness of about 0.1143 to about 0.1397mm (0.0045 to about 0.0055 inches) and a fill ratio of about 90.8 to about 93.2 weight percent of tungsten, which provides a volume of radiopaque material substantially equal to the volume of Platinum/10% Iridium in a 1.0mm long, 0.0635 mm (0.0025 inches) thick (double wall) conventional Platinum/Iridium marker band. Preferably, the volume of radiopaque material is not less than about 30%, and the double wall thickness of the marker is at least about 0.1016mm (0.004 inches), to provide sufficient radiopacity. However, as discussed above, the ability to increase the volume of the marker by increasing the wall thickness of the marker is limited by the resulting increase in profile and stiffness. In a presently preferred embodiment, the double wall thickness of the marker is not greater than about 0.1524mm (0.006 inches).
<figref idref="f0001">Figure 1</figref> illustrates two radiopaque markers 12 attached to the inner member 14 of a balloon catheter 16. During assembly of the catheter 16, the markers are attached to the inner member prior to the positioning of the inner member within the balloon 18 and attachment thereto at 20. Fluoroscopic illumination of the device allows the nonradiopaque balloon to be positioned relative to a lesion by virtue of the visibility of the radiopaque markers under fluoroscopy and their known positions relative to the balloon. The balloon catheter 16 generally comprises an elongated shaft having an inflation lumen and a guidewire lumen, and balloon 18 with a proximal end and distal end sealingly secured to a distal section of the shaft and an interior in fluid communication with the inflation lumen. The shaft typically comprises an outer tubular member defining the inflation lumen, and the inner tubular member 14 extending within at least a portion of the inflation lumen and defining the guidewire lumen.
<figref idref="f0001">Figure 2</figref> illustrates a guidewire with a measurement feature 22 wherein a series of radiopaque markers 24 are attached to the core member of the guidewire at preselected separation distances 26 to allow the device to be used as a type of ruler to measure the size of a lesion. The separation between adjacent markers may be controlled by the use of radiotransparent tubular spacers 28 that are similarly adhered to the underlying guidewire. Upon assembly of the radiopaque markers and the radiotransparent spacers onto at least a distal section of the guidewire core member, heat shrink tubing of sufficient length is slipped over the entire section of guidewire and heated to the appropriate temperature to cause both the markers as well as the spacers to become adhered to the guidewire core member.
<figref idref="f0001">FIG. 3</figref> illustrates an alternative guidewire with a measurement feature 30 wherein an equally spaced series of differently sized radiopaque markers 32a-e are attached to the core member of guidewire 34 to allow the device to be used to gauge the size of a lesion. The separation between adjacent markers may be controlled by the use of a radiotransparent tubular spacers 36 that are similarly adhered to the underlying guidewire. Upon assembly of the radiopaque markers and the radiotransparent spacers onto the guidewire, core member, heat shrink tubing of sufficient length is slipped over the entire section of guidewire and heated to the appropriate temperature to cause both the markers as well as the spacers to become adhered to the guidewire core member.
While a particular form of the invention has been described, it will be apparent to those skilled in the art that various modifications can be made without departing from the scope of the invention. More specifically, markers of different shape and dimensions can be formed and the markers can be attached to any of a variety of medical devices that can benefit from being radiopaquely marked. Accordingly, it is not intended that the invention be limited except by the appended claims.
Contents2
1 sheet
Sheet 1
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| DE102016108783A1 | Cited by | Germany | Search report |
| EP0987042A2 | Cites | European Patent Office (EPO) | Examiner |
| US2003164063A1 | Cites | United States of America | Examiner |
| US4714721A | Cites | United States of America | Examiner |
| EP0987042A2 | Cites | European Patent Office (EPO) | – |
| US2001012968A1 | Cites | United States of America | – |
| US2001021873A1 | Cites | United States of America | – |
| US2003088195A1 | Cites | United States of America | – |
| US2003164063A1 | Cites | United States of America | – |
| US4714721A | Cites | United States of America | – |
| US4935019A | Cites | United States of America | – |
| US6428512B1 | Cites | United States of America | – |
| US6436056B1 | Cites | United States of America | – |
| US6540721B1 | Cites | United States of America | – |
| WO02096474A | Cites | World Intellectual Property Organization (WIPO) | – |
| WO03089012A | Cites | World Intellectual Property Organization (WIPO) | – |
| WO03101343A | Cites | World Intellectual Property Organization (WIPO) | – |
42 members in 10 offices
Priority claims7
| Document | Office | Kind | Date |
|---|---|---|---|
| 667710 | United States of America | – | |
| 66771003 | United States of America | A | |
| 2004030526 | United States of America | W | |
| 2004030526 | – | – | – |
| 667710 | – | – | – |
| US20030667710 | – | – | – |
| WO2004US30526 | – | – | – |
Members42
| Document | Office | Kind | |
|---|---|---|---|
| US2005064223A1 | United States of America | A1 | |
| US2005064224A1 | United States of America | A1 | |
| US2005065434A1 | United States of America | A1 | |
| WO2005030284A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO2005030284A3 | World Intellectual Property Organization (WIPO) | A3 | |
| AU2004311899A1 | Australia | A1 | |
| WO2005065725A1 | World Intellectual Property Organization (WIPO) | A1 | |
| US2005255317A1 | United States of America | A1 | |
| EP1663335A2 | European Patent Office (EPO) | A2 | |
| EP1699493A1 | European Patent Office (EPO) | A1 | |
| HK1089389A1 | Hong Kong, China | A1 | |
| WO2006132850A2 | World Intellectual Property Organization (WIPO) | A2 | |
| CN1901940A | China | A | |
| HK1091759A1 | Hong Kong, China | A1 | |
| JP2007505721A | Japan | A | |
| JP2007525257A | Japan | A | |
| WO2006132850A3 | World Intellectual Property Organization (WIPO) | A3 | |
| US7303798B2 | United States of America | B2 | |
| EP1896093A2 | European Patent Office (EPO) | A2 | |
| US2008065010A1 | United States of America | A1 | |
| JP2008541987A | Japan | A | |
| EP1699493B1 | European Patent Office (EPO) | B1 | |
| AT421890T | Austria | T | |
| ATE421890T1 | Austria | T1 | |
| DE602004019301D1 | Germany | D1 | |
| ES2320351T3 | Spain | T3 | |
| CN1901940B | China | B | |
| US7833597B2 | United States of America | B2 | |
| EP2263708A1 | European Patent Office (EPO) | A1 | |
| US2011070355A1 | United States of America | A1 | |
| CN102000364A | China | A | |
| EP2263708B1 | European Patent Office (EPO) | B1 | |
| JP5059753B2 | Japan | B2 | |
| EP1896093B1 | European Patent Office (EPO) | B1 | |
| US8637132B2 | United States of America | B2 | |
| US2014100447A1 | United States of America | A1 | |
| CN102000364B | China | B | |
| EP1663335B1This record | European Patent Office (EPO) | B1 | |
| ES2546352T3 | Spain | T3 | |
| EP2944333A1 | European Patent Office (EPO) | A1 | |
| EP2944333B1 | European Patent Office (EPO) | B1 | |
| EP3231456A1 | European Patent Office (EPO) | A1 |
71 legal events, as 10 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Opt-out of the competence of the unified patent court (upc) registeredP01 | P01 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed because of non-payment of the annual feeLapsedMM | MM | NL | |
| Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal feeWithdrawnR119 | R119 | DE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Notification of lapseLapsedST | ST | FR | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Fee paymentPLFP | PLFP | FR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| Standard patents granted in hong kongGrantedGR | GR | HK | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filed against granted patent, or epo opposition proceedings concluded without decisionGrantedR097 | R097 | DE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Deletion acc. to par. 5 (withdrawal of the translation of the ep patent)MK05 | MK05 | AT | |
| Translation for ep filed (entry of ep into country)FP | FP | NL | |
| Definitive protectionFG2A | FG2A | ES | |
| Dpma publication of mentioned ep patent grantGrantedR096 | R096 | DE | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| Reference to at number (ep patent validated in austria)REF | REF | AT | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Intention to grant announcedINTG | INTG | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Party data changed (applicant data changed or rights of an application transferred)RAP1 | RAP1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Requests to designate patent in hong kongDE | DE | HK | |
| Request for extension of the european patent (deleted)DAX | DAX | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1663335
- Publication, DOCDB
- 1663335
- Publication, EPODOC
- EP1663335
- Application
- 47888227
- Application, DOCDB
- 04788822
- Application, EPODOC
- EP20040788822
Titles3
- German
- POLYMERMARKER MIT HOHER RADIOPAZITÄT FÜR MEDIZINISCHE GERÄTE
- English
- POLYMERIC MARKER WITH HIGH RADIOPACITY FOR USE IN MEDICAL DEVICES
- French
- MARQUEUR POLYMERE A RADIO-OPACITE ELEVEE DESTINE A DES DISPOSITIFS MEDICAUX
Classification
- CPC, 20
- A61L31/125
- A61B5/1076
- A61B5/6851
- A61B5/6853
- A61B6/12
- A61B6/485
- A61B90/39
- A61B2562/17
- A61F2/958
- A61F2250/0098
- A61L29/18
- A61L31/18
- A61M25/0012
- A61M25/0108
- A61M25/09
- A61M25/1027
- Y10T156/1089
- Y10T428/12493
- Y10T428/1372
- Y10T428/139
- IPC, 7
- A61L29 18
- A61B5 107
- A61B19 00
- A61F2 06
- A61F2 84
- A61L31 18
- A61M25 01
Designated states28
- Contracting states, 28
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czechia
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Hungary
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Poland
- Portugal
- Romania
and 4 moreShow fewer
- Sweden
- Slovenia
- Slovakia
- Türkiye
